Analysis: Docs seek wide HPV vaccine use
8/1/2006 Washingtn, D.C. staff United Press Interenational (www.upi.com) The new vaccine that can prevent about 75 percent of cervical cancer should be given to men, boys and even women already exposed to the virus that causes the disease, researchers said Monday. Although the human papillomavirus (HPV) has been approved for women aged 9 to 26, Bradley Monk, in a commentary to be published in the August issue of the journal Obstetrics and Gynecology, argued that more widespread use of the vaccine may improve the chances that most of cervical cancer can be banished. "We need to work together to implement this huge breakthrough by widespread vaccination of young people, both genders without regard to risk," Monk, assistant professor of obstetrics and gynecology at the University of California-Irvine, told United Press International. HPV, a sexually transmitted disease, is ubiquitous in the United States, with about 20 million men and women currently infected, according to the Centers for Disease Control and Prevention. Moreover, the agency says that about 80 percent of U.S. women by age 50 will be exposed to one of the 100 strains of HPV, known to cause genital warts and cervical, vulva and vaginal cancer in women. The newly approved vaccine called Gardasil -- developed by Merck -- protects against transmission of virus Types 6 and 11, which are believed responsible for 90 percent of disfiguring and difficult-to-treat genital warts, and against Types 16 and 18, responsible for 70 percent to 75 percent of cervical cancer -- a disease [...]